VAM
TRIB

Visium Asset Management’s Trinity Biotech TRIB Stock Holding History

Visium Asset Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-30,000
Closed -$3.46M – 1216
2014
Q2 		$3.46M Buy
+30,000
New +$3.56M 0.05% 298

Other funds holding TRIB

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

Visium Asset Management's TRIB Position: Q3 2014 in Review

Visium Asset Management sold out of Trinity Biotech (TRIB) in Q3 2014, closing a stake of 30,000 shares — an estimated $3.46M sold.

Visium Asset Management first reported a position in TRIB in Q2 2014 and held it in 1 quarter. The position peaked at $3.46M in Q2 2014. 95 funds tracked by Wall St. Rank hold TRIB as of Q3 2014.

  • Visium Asset Management reported no remaining Trinity Biotech position as of Q3 2014 after selling out during the quarter.
  • Visium Asset Management sold 30,000 Trinity Biotech shares in Q3 2014, an estimated $3.46M.
  • Visium Asset Management first reported a position in Trinity Biotech in Q2 2014 and held it in 1 quarter.
  • Visium Asset Management's Trinity Biotech position peaked at $3.46M in Q2 2014.
  • 95 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2014.

Based on Visium Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.